May 14, 2014
Cornerstone Pharmaceuticals Clinical Data on CPI-613 to be Presented at ASCO 2014
Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from a Phase I clinical trial of its proprietary first-in-class anticancer compound CPI-613 in patients with relapsed or refractory acute myeloid leukemia will be presented during a Poster Highlights Session at the ... (more)
The Cary News
Cornerstone Therapeutics of Cary renamed Chiesi
Cornerstone Therapeutics of Cary became Chiesi USA on Monday, finalizing a $300 million acquisition by Italian drug maker Chiesi Farmaceutici.
Chiesi Group Reports Double-Digit Growth and International Expansion
Chiesi Farmaceutici SpA, an international pharmaceutical company focused in the respiratory, neonatology and special care therapeutic areas, closed 2013 with a turnover of more than 1,236 million euro, an increase of 11.8% compared to 2012 .
Cornerstone Pharmaceuticals Lead Compound CPI-613 Demonstrates...
Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that its first-in-class cancer metabolism targeted therapeutic, CPI-613, demonstrated the ability to inhibit tumor cell growth in the published studies.
Digestive Care, Inc. Donates Year-Long Supply of PERTZYE(R)...
The donation is part of an ongoing charitable program sponsored through collaboration with John Stevens, MD, Professor of Clinical Pediatrics at Indiana University, and CF care physician at the James Whitcomb Riley Hospital for Children CF Center in Indianapolis.